Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.35 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 4/20 | 0.33 |
| ▸ | MELK | Q14680 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18057520 | 0.92 | HRH4 (0.37) | HRH4MEN1KMT2APARP1KDM4E | |
| SCHEMBL18057547 | 0.89 | PDE4B (0.38) | HRH4MRGPRX2PARP1MELKKDM4E | |
| SCHEMBL18057544 | 0.88 | ALDH1A1 (0.39) | HRH4KMT2APARP1KDM4E | |
| SCHEMBL18057523 | 0.87 | HRH4 (0.40) | HRH4MEN1KMT2APARP1KDM4E | |
| SCHEMBL18057495 | 0.85 | JAK2 (0.37) | HRH4MRGPRX2MEN1KMT2AEHMT2 | |
| SCHEMBL18057530 | 0.84 | HRH4 (0.36) | HRH4MEN1KMT2APARP1KDM4E | |
| SCHEMBL18057491 | 0.84 | MELK (0.34) | HRH4MRGPRX2EHMT2EHMT1MELK | |
| SCHEMBL18057517 | 0.80 | PDE4B (0.40) | HRH4PARP1KDM4ECDK6 | |
| SCHEMBL18057537 | 0.80 | PARP1 (0.40) | HRH4KMT2APARP1KDM4E | |
| SCHEMBL18057512 | 0.78 | JAK2 (0.38) | HRH4MEN1KMT2APARP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745403-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10590134-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-9951066-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2018-03-22 | — | — | US | disclosed |
| US-20170334905-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2017-11-23 | — | — | US | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590134-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | HRH4 4586/4885MRGPRX2 1662/4885MEN1 2100/4885 |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | HRH4 4546/4885MRGPRX2 1441/4885MEN1 3023/4885 |
| US-10745403-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | HRH4 4586/4885MRGPRX2 1662/4885MEN1 2100/4885 |
| US-20170334905-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | HRH4 4546/4885MRGPRX2 1441/4885MEN1 3023/4885 |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | HRH4 4546/4885MRGPRX2 1441/4885MEN1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.